A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patientsMasashi Kanai, Hiroyuki Shibata|Cancer Chemotherapy and Pharmacology|2013Cited by 191
Curcumin β‐D‐glucuronide exhibits anti–tumor effects on oxaliplatin‐resistant colon cancer with less toxicity in vivoHitomi Ozawa‐Umeta, Masashi Kanai|Cancer Science|2020Cited by 29